Exagen Future Growth
Future criteria checks 1/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Exagen.
Earnings growth rate
EPS growth rate
|Biotechs earnings growth||48.9%|
|Revenue growth rate||17.4%|
|Future return on equity||n/a|
|Last updated||22 May 2023|
Recent future growth updates
Earnings and Revenue Growth Forecasts
|Date||Revenue||Earnings||Free Cash Flow||Cash from Op||Avg. No. Analysts|
Analyst Future Growth Forecasts
Earnings vs Savings Rate: E08A is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: E08A is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: E08A is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: E08A's revenue (17.4% per year) is forecast to grow faster than the German market (4.3% per year).
High Growth Revenue: E08A's revenue (17.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if E08A's Return on Equity is forecast to be high in 3 years time